Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives

Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have emerged as a major mediator of immunosuppression in the tumor microenvironment that promotes progression of various tumor types. The main mechanisms underlying MDSC-induced immunosuppression are currently being explored and strategies to enhance anti-tumor immune response via MDSC targeting are being tested. However, the role of MDSCs in PCa remains elusive. In this review, we aim to summarize and present the state-of-the-art knowledge on current methodologies to phenotypically and metabolically characterize MDSCs in PCa. We describe how these characteristics may be linked with MDSC function and may influence the clinical outcomes of patients with PCa. Finally, we briefly discuss emerging strategies being employed to therapeutically target MDSCs and potentiate the long-overdue improvement in the efficacy of immunotherapy in patients with PCa.

Automated summary

This article reviews the research progress on mechanisms involved in the response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have been identified as a major mediator of immunosuppression in the tumor microenvironment and strategies to enhance anti-tumor immune response via MDSC targeting are being explored. The article summarizes the current methodologies for phenotypic and metabolic characterization of MDSCs in PCa and discusses their potential impact on clinical outcomes. Additionally, emerging strategies for therapeutically targeting MDSCs are briefly discussed.